Month: April 2024

Publication of annual report 2023 and convening notice for the General Meeting Regulatory release 5 April 2024, 8 a.m. CET Kinepolis Group presents its integrated annual report 2023, with a comprehensive overview of the Group’s strategic, financial, operational and ESG performance for the year 2023. The non-financial information section is available in Dutch, French and English. The financial report is available in Dutch and English. Link to the 2023 annual report. The Ordinary General Meeting will take place on Wednesday 8 May 2024 at 10 a.m. at the registered offices of Kinepolis Group NV (Eeuwfeestlaan 20, 1020 Brussels). Link to the reports, convening notice, proxy and other documents. Link to the ABN-AMRO platform to participate in the meeting. Contact Kinepolis Press Office                                        Kinepolis Investor...

The Supervisory Council of AS Tallinna Vesi approved the audited financial results for 2023. The financial results have not changed from the unaudited results published on 2 February 2024. The company’s sales revenue in 2023 was €61.14 million, compared to 2022, the sales revenue increased by 12.1%, or €6.58 million. The change in sales revenue was due to the tariff, adjusted by the increase in energy costs, which took effect on 01/10/2022. Revenue from the sale of water services increased by 13.8% to €55.62 million. The revenue from the sale of construction services was €4.77 million, which is 0.7% less than a year before.  Last year’s operating profit amounted to €17.35 million, almost recovering to 2021 levels and increasing by 53.3%, or €6.03 million, compared to the significantly lower base in 2022. The growth in operating profit...

Issuer name: Ensurge Micropower ASA Ex. date: 5 April 2024 Type of corporate action: Share consolidation (reverse share split) Former ISIN: NO0012450008 New ISIN: NO0013186460 This information is published in accordance with the requirements of the Continuing Obligations.

Utstedernavn: Ensurge Micropower ASA Ex. dato: 5. april 2024 Type selskapshandling: Aksjespleis Gammel ISIN: NO0012450008 Ny ISIN: NO0013186460 Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser.

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) — Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD), a company focused on opportunities within and outside of the cannabis industry, announces that it has granted 1,696,815 restricted share units (the “RSUs“) to certain directors and officers of the Company. The RSUs are granted pursuant to the terms of the RSU Plan approved by the shareholders of the Company and are subject to the policies of the Canadian Securities Exchange. About Digicann Ventures Inc. Digicann Ventures Inc. is a company focused on opportunities within and outside of the cannabis industry. For more information about Digicann Ventures Inc. please visit www.digicann.io and its profile page on SEDAR at www.sedarplus.ca. ON BEHALF OF THE BOARD OF DIRECTORS Nick...

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) — Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. Proceeds will be used for general working capital purposes. No insiders participated...

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) — Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need, today announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share. All of the shares are being offered by Contineum. The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million. The shares are expected to begin trading on The Nasdaq Global...

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, announces March 2024 preliminary mining results: DMG mined 49.8 bitcoin with 1.0 EH/s realized hashrate. DMG’s bitcoin balance as of March 31, 2024 was 446 bitcoin. DMG Management at the DigitalABC’s First Annual Blockchain Law, Regulation and Policy Conference on April 8 in Ottawa, Canada DMG management will appear on panel discussions for the first annual Blockchain Law, Regulation and Policy Conference & Reception held on April 8, 2024 at the Sheraton Ottawa, organized by the Digital Asset Business Council (DigitalABC) as well as the Canadian Blockchain Consortium. Key topics to...